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In the present study, we reported two cases of renal cell carcinoma (RCC) diagnosed in pregnant women
(Pt) that were submitted to radical nephrectomy, in both cases within the fourth month. The patients, after
13 and 3 years, respectively, did not show evidence of recurrent disease. We performed an immunohisto-
chemical study on RCC specimens in comparison to seven age-matched controls (Cl). The panel of anti-
bodies included Ki-67, p53, bcl-2, ER, PgR, PCNA, and IGF-1. We describe a difference in the expression of
p53 and Ki-67. Specifically, p53 was highly expressed in RCC of both Pt but scarcely present or absent in
Cl; by contrast, Ki-67 was hardly expressed or negative in RCC of both Pt, being commonly positive in Cl.
These results may correlate with a good outcome of the disease in Pt. Although the limited number of ca-
ses did not permit any statistical evaluation, we postulate that these differences have not to be under-
estimated since they may disclose a correlation between pregnancy and biological behavior of tumoral
disease. Further study may (dis)prove this hypothesis.
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Pregnancy and renal cell carcinoma (RCC) share the
fact that they are tolerated by an intact immune sys-
tem(1–3). Moreover, there are evidences in the literature
suggesting that the number of births could influence
the risk of RCC compared with nulliparous women,
the risk being nearly two times higher among pluri-
parous women(4).
RCC is a rare tumor in fertile women, and its diag-
nosis during pregnancy is even rarer, with 35 reported
cases in a literature review of 1986(1) and about 20
added during the following 20 years(5–11).
In the present work, we examined retrospectively
two female patients with asymptomatic low-stage
renal tumors discovered at routine ultrasound exami-
nation during pregnancy, comparing them to a series
of age-matched controls.
Materials and methods
We examined histologic specimens from both a 25- and
a 32-year-old female patient who were found to have
left-sided renal tumors (Pregnant tumors, Pt) during
routine ultrasound examination of their abdomens for
pregnancy. They both underwent nephrectomies at the
fourth month of pregnancy through a flank approach,
and they completed their pregnancies at term. The tu-
mors measured 2.5 and 3 cm in maximum diameter,
respectively, and the staging for both cases was pT1
(following the 2002 guidelines of International Union
Against Cancer). Further examinations disclosed no
evidence of metastatic disease. These patients have
been followed for 13 and 3 years, respectively, and
there has been no evidence of relapse.
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As controls, we selected seven fertile female patients
aged between 25 and 35 years presenting pT1 G1–2
N0 M0 RCCs (controls, CI) treated with radical
nephrectomy during a 20-year period. All the Cl were
incidentally discovered and were asymptomatic RCC,
confined within the renal capsule, with no evidence
of local recurrence during the scheduled follow-up
evaluation.
The specimens were obtained by surgical resection
in all cases and fixed in 10% buffered formalin before
being embedded in paraffin. Hematoxylin and eosin–
stained sections from each specimen were reviewed
by three pathologists (G.N., E.M., and F.C.) to confirm
the histologic diagnosis. Sections of 4 lm for each
lesion were obtained for immunohistochemical analy-
ses. All sections were deparaffinized in Bio-Clear (Bio-
Optica, Milan, Italy), hydrated with graded ethanol
concentration, and rinsed in distilled water. To block
endogenous peroxidase activity, slides were treated
with 3.0% hydrogen peroxide in distilled water for
20 min. The sections were incubated with the follow-
ing antibodies for 1 h at room temperature: anti-bcl-2
protein (clone 124, DakoCytomation, Glostrup A/S,
Denmark; dilution: 1:40); anti-Ki-67 antigen (clone MIB-1,
DakoCytomation; dilution: 1:80); anti-p53 protein
(clone D07, DakoCytomation; dilution: 1:40); anti-ER
(clone 6F11, Ventana Medical Systems, Tucson, AZ;
dilution: 1:100); anti-PgR (clone 16, Ventana Medical
Systems; dilution: 1:100); anti-PCNA (clone PC10,
DakoCytomation; dilution: 1:100); and anti-IGF-1 (clone
BM23, Cymbus Biotechnology, Hampshire, UK; dilu-
tion: 1:100).
All sections designated for heat-induced epitope re-
trieval were placed in a 10 mM/L citrate buffer, pH 6.0,
heated in a microwave oven for histology (Microwave
MicroMed T/T Mega, Milestone, Bergamo, Italy) for 35
min, followed by cooling for 20 min at room tempera-
ture. Staining was achieved using a biotin-conjugated
anti-mouse and anti-rabbit secondary antibody (Ultra-
Vision, Fremont, CA), and subsequently, the streptavi-
din–peroxidase (UltraVision) was applied to all
sections. The bound antibodies were visualized using
3,39 diaminobenzidine (BioGenex, San Ramon, CA) as
the chromogen. Nuclei were slightly counterstained
with Mayer’s hematoxylin. Negative control was per-
formed by substituting the primary antibody with
a nonimmune serum at the same concentration. For
positive control, a follicular lymphoma section was
used for bcl-2 protein and Ki-67 antigen. For p53, we
used a section of squamous cell laryngeal carcinoma
with nuclear reactivity; for ER and PgR, human breast
tumor sections known to be positive for these steroid
hormone receptors; and for IGF-1, human kidney
tissue. Overall tissue expression was scored as follows:
0, no staining; 11, 1–10% staining; 21, 11–50% stain-
ing; and 31, 51–100% staining. Immunohistochemical
results were evaluated in a blinded manner without
knowledge of the clinical data.
Results
In both Pt cases, histopathologic regressive aspects were
documented, consisting of fibrosis, lymphocytic infiltra-
tion, cystic aspect, and hemorrhagic necrosis (Fig. 1A).
A strong expression of p53 protein was detected in
both Pt (Fig. 1B), whereas it was present in only one
of the seven Cl and with a light immunoreactivity
(Table 1). By contrast, occasional Ki-67-positive cells
were observed in only one of the Pt (Fig. 1C), while
Ki-67 positivity was higher in all but one Cl.
Concerning the other markers, no consistent differ-
ences of expression of studied markers were found
(Table 1). In particular, ER and PgR were present in
one Pt and in three of seven Cl, bcl-2 in one Pt and
four of seven Cl, and IGF-I in both Pt and five of seven
Cl (Fig. 2A, B).
Discussion
To our knowledge, there is no evidence in the literature
to suggest that pregnancy influences the clinical course
of RCC, although it has been reported that pregnancy
and cancer are biologic conditions in which antigenic
tissue is tolerated by immune system(1,12). In particular,
a condition of immunosuppression, characterized by
decreased cellular immunity, circulating serologic
blocking factors and hormones with immunosuppres-
sive effects, allows maternal tolerance of the fetus.
The number of births could influence the rise of
RCC compared with nulliparous women, the risk being
nearly two times higher among pluriparous women(4).
The regressive features of renal carcinomas consist of
extensive fibrosis with marked lymphocyte; moreover,
plasma cell infiltrate is frequent and could be ascribed
to the high levels of hormones (specifically pro-
gesterone) during pregnancy. Abdominal sonography
performed during the first trimester allows the diagno-
sis of low-stage tumors in asymptomatic patients.
We presently investigated if there were biological dif-
ferences between Pt and Cl by immunohistochemistry.
The Ki-67 nuclear antigen is expressed at all phases of
the cell cycle in a proliferating cell and represents an
excellent marker of cell proliferation in histologic speci-
mens; the p53 tumor suppressor gene has been proved
to participate in cellular DNA damage, resulting in
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either growth arrest or apoptosis. Wild-type (wt) p53
has a short half-life, and it is commonly negative at
immunohistochemistry; by contrast, when mutated,
p53 accumulates and becomes immunohistochemically
Figure 1. A) Pt display extensive fibrosis and marked lymphocytic
infiltration (Hematoxylin–eosin, original magnification 3100). B)
Nuclear immunopositivity for p53 oncoprotein in a case of Pt (dia-
minobenzidene, original magnification 3200). C) Occasional nuclear
Ki-67 immunopositivity in Pt (diaminobenzidene, original magnifi-
cation 3400).
Table 1. Comparison of immunohistochemical results
between the two cases of renal cell tumors diagnosed in preg-
nant women and the seven age-matched controls (Cl)
Pregnant women Cl
A B 1 2 3 4 5 6 7
PCNA 1 1 1 1 1 1 1 1 1
Ki-67  2 11 11 11 1 11 1 2
ER 1 2 2 1 11 2 2 1 2
PgR 1 2 2 2 11 2 1 1 2
p53 111 111 1 2 2 2 2 2 2
Bcl-2 11 2 1 1 1 11 2 2 2
IGF-1 111 111 11 2 2 11 11 11 11
Figure 2. A) Bcl-2 negative staining of tumor cells. Interstitial lympho-
cytes are positive (LSAB, original magnification 3250). B) High IGF-1
expression in renal carcinoma (LSAB, original magnification3250).
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detectable(13). Mutated p53 loses its ability to induce
apoptosis(14). Recent reports show that p53 mutation is
not frequently present in renal carcinoma(15).
We consider of interest the results of immunohisto-
chemistry for p53 and Ki-67. In particular, Pt seem to
show higher immunoreactivity for p53 than Cl; by
contrast, Ki-67 was scarce or absent in Pt and positive
in all Cl except one.
Although intuitively, these discrepancies may be
due to an earlier diagnosis and consequently an earlier
stage of disease of Pt, we cannot exclude that immu-
nosuppression of pregnancy stimulates growth of
mutated p53 cells, while normal immune system could
select clones of wt p53 tumoral cells. This hypothesis
is supported by recent studies that indicate a proim-
munitary role of mutated p53 during carcinogene-
sis(16,17). In addition, an in vivo study showed that p53
may represent a target for CD81 T cells in a pro-
portion of individuals with cutaneous squamous cell
carcinomas(16).
The correlation between increased proliferative
index and higher apoptotic index(18–20) may explain
why clones of wt p53 have a higher proliferative
index. In addition, simultaneous overexpression of
p53 and Ki-67 was reported in early stages of tumori-
genesis(21), while p53-negative and Ki-67-positive tu-
moral immunophenotypes were already associated
significantly with an unfavorable outcome(22).
Finally, concerning the discrepancies between Ki-67
and PCNA immunopositivity, we know that the for-
mer antigen is expressed in all cycling cells, whereas
the latter reveals only the S-phase fraction; differences
between Ki-67 and PCNA scores were already
described in breast cancer(23), transitional cell carci-
noma(24), laryngeal epithelial lesions(25), endometrial
adenocarcinoma(26), and oral leukoplakia(27), being
commonly accepted that Ki-67 seems to be more con-
sistent for use in therapeutic clinical trials.
In conclusion, this work may be considered a pilot
study, and further analyses on wider series could (dis)-
prove the hypothesis that pregnancy could be related
to a better outcome of patients with tumors.
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